UBS Maintains Neutral on Chemours, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 83.1%

Neg 83.1% Neu 0% Pos 0%

UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.

Comments

No comments yet. Be the first!